STEREOSELECTIVE PERCUTANEOUS ABSORPTION AND TRANSDERMAL DELIVERY OF CHIRAL DRUGS by E. Alberti
UNIVERSITÀ DEGLI STUDI DI MILANO 
Facoltà di Farmacia 
Dipartimento di Scienze Farmaceutiche “P. Pratesi” 
 
 
 
CORSO DI DOTTORATO DI RICERCA IN CHIMICA DEL FARMACO 
XXIII CICLO 
SETTORE CHIM/09 FARMACEUTICO TECNOLOGICO APPLICATIVO 
 
TESI DI DOTTORATO DI RICERCA 
 
STEREOSELECTIVE PERCUTANEOUS ABSORPTION AND 
TRANSDERMAL DELIVERY OF CHIRAL DRUGS  
 
 
Dr.ssa Elisabetta Alberti 
 
 
Tutor: Prof.ssa Luisa Montanari 
Coordinatore del dottorato: Prof. Carlo De Micheli 
 
 
 
Anno Accademico 2009-2010 
Table of content 
 
Table of content 
 
Introduction            p.  1 
 
Chapter 1: An Investigation into the Influence of Counterion on the  
RS-Propranolol and S-Propranololskin permeability     p.  5 
 
Chapter 2: Formulation study of a patch containing propranolol    p. 22 
 
Chapter 3: Effect of drug chirality and supersaturation  
on the skin permeability of ibuprofen       p. 44 
 
Conclusions           p. 59 
 
Introduction 
  
1 
 
 
 
 
 
 
Introduction 
Introduction 
  
2 
The selection of the enantiomeric or racemate form of a drug is a critical issue in the 
development of transdermal dosage forms. Indeed, the stratum corneum, the rate-limiting 
barrier to percutaneous absorption, is mainly composed by keratin and ceramides, which 
could potentially provide a chiral environment. Therefore, the different binding of 
enantiomers to keratin or the interactions with ceramides may give rise to differences in the 
permeation profiles of the enantiomers of chiral molecules [1].  
The evaluation of enantiomeric intrisic stereoselectivity is critical because high drug 
concentrations can overcome the enantioselective interactions. Moreover, organic solvents in 
the donor vehicle can cause conformational changes in keratin and ceramide molecules [4]. In 
addition to the intrinsic stereoselectivity of the skin for enantiomers, extrinsic factors such as 
differences in physicochemical properties between enantiomers and racemate may also be 
implicated in enantioselective permeation [2, 3]. Stereoisomers of chiral compounds having 
melting points lower than those of the corresponding racemates, are associated with higher 
solubility and thermodynamic activity and, consequently, greater flux through the skin [4]. 
The opposite behaviour was evidenced when the enantiomer exhibited higher melting point 
than the racemate [5]. 
A mathematical model, the melting temperature-membrane transport (MTMT) concept, based 
on the interdependence of the physicochemical characteristics and the membrane transport 
behaviour of a chiral penetrant, was used to predict the permeability ratio of enantiomer and 
racemate of chiral molecules [3,4]. This model resulted effective to predict the membraneal 
transport when the difference between the melting temperatures of the pure enantiomers and 
the racemate is high [6].  
Whereas the implication of different physicochemical properties between enantiomers and 
racemate in the in vitro skin permeation profiles have been studied, other aspects such as the 
effect of different counter-ions of ionisable chiral drug and different enantiomer of chiral 
permeation enhancers on skin permeability have not yet been extensively investigated. 
This work was therefore focused on these two topics to deep actual understanding and to 
obtain information useful to rationalize the development of transdermal patches.  
Among the chiral drugs, propranolol (PR) and ibuprofen (IB) were selected.  
PR is a good candidate as its biological activity is largely associated to a single enantiomer. In 
humans, S-PR is about 100 times more potent than the R-enantiomer as β-blocker [7] and the 
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information reported in literature about the in vitro skin permeability suggest that it can be a 
suitable candidate to transdermal delivery [3].  
In the case of IB, largely used in the treatment of musculoskeletal injuries, only the S-
enantiomer (S-IB) is therapeutically active, and extensive unidirectional chiral enantiomeric 
inversion of R to S occurs in vivo [8]. Studies indicates that there aren’t any evidences for the 
metabolic inversion after topical administration [9]. Till now, although the biological activity 
of IB resides with the S-enantiomer, the topical preparations available on the market contain 
the racemate. 
This work aimed to determinate the skin permeability profiles of the selected drugs and in 
some case of the their salts, in order to evaluate the enantio-selectivity in the diffusion 
process. The salts were obtained salifing the drug, either as racemate and pure enantiomer, 
with different counter-ions, selected on the bases of their physico-chemical characteristics.  
The experiments were performed by the modified Franz cell method, using human skin 
epidermis as a membrane [10] and selecting the donor phase on the bases of the drug 
solubility. Suitable analytical methods for the quantitative determination of the drugs were 
developed. As a first step the skin permeability test was conducted by using saturated or 
diluted solutions. 
On the bases of the preliminary permeability data, the formulation study of monolayer 
transdermal patches containing the drug in its most appropriate form , and, if necessary, the 
suitable promotion enhancer, was carried out.  
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1. Introduction 
 
The use of a drug as an enantiomer or a racemate is become a critical issue in the 
development of transdermal dosage forms. Indeed, other than the biological activity of the 
single enantiomer, the chirality of the skin has to be taken into account, because differential 
binding of enantiomers to keratin or interactions with ceramides may give rise to differences 
in the permeation profiles of the enantiomers [1]. In addition to the intrinsic stereoselectivity 
of the skin for enantiomers, extrinsic factors such as differences in physicochemical properties 
between enantiomers and racemate may also be implicated in enantioselective permeation [2, 
3]. It has been described that the stereoisomer of chiral compounds with a lower melting point 
than their racemates have usually higher solubility and thermodynamic activity and, 
consequently, greater flux through the skin than those of the racemates [4]. The opposite 
behaviour was found when the enantiomer exhibits higher melting point than the racemate 
[5]. A mathematical model, the melting temperature-membrane transport (MTMT) concept, 
based on the interdependence of the physicochemical characteristics, namely melting 
temperature and membrane transport behaviour of a chiral penetrant, was used to predict the 
permeability ratio of enantiomer and racemate of chiral molecules [6, 7]. 
Skin permeability of a ionisable drug is not only influenced by its physico-chemical 
characteristics but also by the counter ion. The skin permeability of piroxicam was increased 
by salification with ethanolamines and the enhancement effect resulted proportional to the 
molecular volume of the counter-ion [8]. Organic salts of diclofenac from aqueous solution 
permeated better through human skin than the inorganic salts [9]. 
Propranolol is a chiral β-adrenergic blocker which undergoes to extensive first-pass hepatic 
metabolism and exhibits suitable phisico-chemical characteristic for transdermal delivery. The 
skin permeability of propranolol through human skin was reported in several papers. The 
results showed that the enantiomers exhibited a higher permeability through human skin than 
the racemate when propranolol base was used [6]. The effect of several skin enhancers on the 
permeability of the propranolol HCl through porcine epidermis was also studied [10]. From 
the literature data, it can be extrapolated that the skin permeation of the unionized form was 
higher than the hydrochloride one. Nevertheless, the effect of contra-ions on the diffusion of 
propranolol through human epidermis has not been systematically investigated. 
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In the present work, the effect of two different contra-ions, namely benzoate and oleate, on 
the human skin permeability of propranolol racemate or enantiomer was studied. Such 
propranolol salts were selected as the solid state characteristics of the racemate have been 
already reported in literature [11, 12], but their in vitro permeability through human epidermis 
has not yet been described. Moreover, to the best of our knowledge, no informations on      
(S)-propranolol oleate and (S)-propranolol benzoate solid state are reported in literature. 
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2. Experimentals 
 
2.1. Materials 
(RS)-Propranolol, (RS)-PR, (S.I.M.S., Italy); benzoic acid (Fluka Chemie AG, Switzerland); 
oleic acid (Sigma-Aldrich S.r.l., Italy). All the solvents, unless specified, were of analytic 
grade (Carlo Erba, Italy).  
 
2.2 Enantiomeric separation and salt preparation 
(S)-Propranolol hydrochloride was prepared by resolution of the racemic propranolol via 
selective crystallization of the diastereomeric salts with (-)-dibenzoyltartaric acid according to 
the proceduresreported in literature [13, 14]. Such classical resolutions involve the 
precipitation of (S)-propranolol ((S)-PR) neutral dibenzoyltartrate with moderate to high 
diastereomeric excess from a methanolic solution containing equivalent amounts of racemic 
aryloxypropanolamine and resolving laevorotatory diacid (2:1 molar ratio). The enantiomeric 
excess of the liberated S base was successively maximized at >99% through three 
crystallizations of its hydrochloride from ethanol. 
The resolution progress was monitored by chiral HPLC of propranolol liberated from samples 
of the precipitated salts (the neutral dibenzoyltartrate and the three hydrochlorides) finding an 
increased enantiomeric purity of the aryloxypropanolamine after each crystallization. (S)-PR 
was quantitatively liberated from its hydrochloride by treatment of this latter with 3 N NaOH 
and toluene or diethyl ether and concentration of the dried organic phase. (S)-propranolol 
benzoate and (RS)-propranolol benzoate ((S)- and (RS)-PR-Bz) were precipitated from 
ethereal solutions of the free base, (S)-PR and (RS)-PR respectively, by addition of equivalent 
ethereal benzoic acid. 1H NMR (CDCl3 + D2O ) δ 8.20 (d, 1 H), 8.08 (dd, 2 H), 7.77 (d, 1 H), 
7.25-7.48 (m, 7 H), 6.73 (d, 1 H), 4.68-4.76 (m, 1 H), 4.24 (dd, 1 H), 4.12 (dd, 1 H), 3.25-3.43 
(m, 3 H), 1.41 (2 d, 6 H). 
(S)-propranolol oleate and (RS)-propranolol oleate ((S)- and (RS)-PR-Ol) were prepared by 
combining equivalent chloroformic solutions of oleic acid and amine, S and RS respectively, 
and evaporating the solvent to give the fatty acid ammonium salts as waxy solids. 1H NMR 
(CDCl3) δ8.22 (d, 1 H), 7.80 (d, 1 H), 7.40-7.52 (m, 3 H), 7.34 (t, 1 H), 6.80 (d, 1 H), 5.78 (br 
s, 3 H, disappears on exchange with D2O), 5.32 (m, 2 H), 4.50 (m, 1 H), 4.26 (dd, 1 H), 4.11 
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(dd, 1 H), 3.14-3.28 (m, 2 H), 3.08 (dd, 1 H), 2.26 (t, 2 H), 2.00 (m, 4 H), 1.60 (m, 2 H), 1.16-
1.38 (m, 26 H), 0.88 (t, 3 H). 
 
2.3 Physico-chemical characterization 
2.3.1 Differential Scanning Calorimetry (DSC) analyses 
DSC scans were recorded by using a DSC 2010 TA (TA Instruments, USA). Samples 
(approximately 5 mg, accurately weighed, ±0.01 mg) were heated in open aluminium pans 
under nitrogen purging (70 mL min–1). The reference was an empty pan. The equipment was 
calibrated with an indium sample. All samples were scanned at 10 K min–1 from -10°C to 
200°C. All determinations were performed in duplicate. 
 
2.3.2 Solubility determination 
The solubility of the compound was determined in saline solution (0.9% w/v NaCl) and 
mineral oil at 32ºC. The samples were stirred at 60±1ºC for two hours and then at 32±1ºC for 
48 hours to obtain saturated solutions. The solute in excess was removed by filtration. The 
saturated solutions in saline solution and mineral oil were opportunely diluted in the mobile 
phase or in eptane, respectively, and then analyzed by the HPLC method described in section 
2.5 or UV-spectrometry (wavelength: 295 nm; DU® 640 SPECTROPHOTOMETER, Beckam 
Coulter, USA). The results are expressed as mean ± st.dev. (n=3). 
 
2.3.3 Apparent partition coefficient determination: shake flask method 
N-octanol and physiologic solution were mutually saturated at the temperature of 23° C. N-
octanol solutions of known concentration of the compounds were prepared. A centrifuge tube 
was filled with a chosen volume ratio of n-octanol solution containing the active ingredient 
and saline solution and vigorously shaken hundred times over five minutes. The separation of 
the two phases was achieved by centrifugation and the aqueous phase was assayed to 
determine the concentration of the tested substance using the HPLC method described in 
section 2.5. 
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2.3.4 Determination of the micellar critical concentration of (RS)-PR-O and (S)-PR-O 
The micellar critical concentration was determinated using a particle sizing analyzer 
(ACCUSIZERTM 780 A, PSS NICOMP, USA). Eight solutions of known concentrations, 
ranging between 2 and 200 µg/mL, of racemic and enantiomeric forms of propranolol oleate 
were prepared in saline solution. A volume of 20 mL of each solution was analyzed by gravity 
drain at 23°C and the area weighted mean diameters were recorded. All the mesurements 
were corrected by subtracting the saline solution. 
 
2.4 Skin permeation experiment 
The abdominal skin was obtained from a donor (Eurasian female) who underwent cosmetic 
surgery. The excess of fat was carefully removed and the skin sections were cut into squares. 
The fullthickness skin was sealed in evacuated plastic bags and frozen at -20°C within 24 h 
after removal. Then, the skin was thawed at room temperature, and, after immersing the skin 
in water at 60°C for 1 min, the epidermis was gently separated from the remaining tissue. The 
epidermis was carefully inspected visually for any defects. The epidermis was mounted 
carefully on the modified Franz cell. The upper and lower parts of the Franz cell were sealed 
with Parafilm® and fastened together by means of a clamp. The receiver compartments were 
filled with degassed physiological solution. The Franz cells were kept at 37°C, so that the 
epidermis surface temperature was 32±1°C. After an hour, 1 mL of freshly prepared drug 
saturated solution was added to each donor compartment. To maintain the propranolol 
solution saturated, an excess amount of solute was added into the donor compartment. The 
donor solutions were prepared as described in the solubility determination section. The pH 
values of the saturated solutions were about 9 for the free bases and ranging from 6.2 to 6.6 
for the salts. At predetermined times (1, 3, 5, 7, 24 h) 0.2 mL samples were withdrawn from 
the receiver compartment and immediately replaced with fresh receiver medium. Sink 
conditions were maintained throughout the experiment. The receiver mediums recovered at 
the end of each experiment were also analyzed to evaluate if an enantioselective permeation 
occurred when the racemates were used and to determine the amounts of contra-ions 
permeated through the skin. Each experiment was performed in triplicate. 
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2.5 HPLC analysis 
The HPLC apparatus was HP 1100 (Chemstations, Agilent Technologies, Italy). Injection 
volume: 20 µL; flow rate: 1.0 mL/min; UV absorbance: 225 nm. Column: C18 reverse-phase 
(Bondclone, 10µm, 3.90x300 mm; Phenomenex, USA). Mobile phase: acetonitrile/0.2% 
phosphoric acid 30/70 v/v. Temperature: 25°C. Three standard calibration curves (0.005-5 
µg/mL; 1-40 µg/mL; 10-200 µg/mL) were used. The limit of quantification was 0.004 µg/mL. 
Resolution from the background noise was adequate at this level. The calibration curves were 
prepared by using known concentrations of (RS)-PR in the mobile phase. 
In the case of the permeation experiment performed by using the racemate, samples 
withdrawn after 24 h were also assayed by the method described below. A 5 mL sample was 
freeze-dried (ALPHA 1-4 LSC, CHRIST, Germany) and then chiral HPLC analyses were 
performed on a Kromasil 5AmyCoat column (250x4.6 mm). Injection volume: 10 µl; flow 
rate: 1.0 mL/min; UV absorbance: 225 nm. Mobile phase: hexane/methanol added with 0.1% 
diethylamine 80:20 v/v. Temperature: 25°C. Under these analytical conditions, (S)-PR 
(retention time: 12 min) was eluted after (R)-PR (retention time: 8 min). A standard 
calibration curve (1-50 µg/mL) was used. The dry samples were also used to determine the 
amount of contra-ions permeated after 24 h. The quantification was performed eluting the 
oleate in acetonitrile (quantification limit 5 µg/mL) and the benzoate in 
acetonitrile/water/phosphoric acid 60/40/0.2 v/v/v (quantification limit 0.008 µg/mL) at the 
flow rate of 1 mL/min by using an ACE 5 C18 column (250x4.6 mm) (CPS analytical, Italy). 
The UV absorbance was set at 200 nm in the case of oleate and 225 nm for the benzoate. 
 
2.6 Data analysis 
The cumulative amount permeated through the skin per unit area was calculated from the 
concentration of each substance in the receiving medium and plotted as a function of time. 
The steady flux (Jmax) was determined as the slope of the linear portion of the plot. The 
permeability coefficient was calculated according to Fick’s first law of diffusion (equation 1): 
S
J
K P
max=  (1) 
where Kp (cm/h) is the permeability coefficient, Jmax (µg/cm2 per h) is the flux obtained with 
the saturated solution and S is the drug donor concentration (µg/cm3), corresponding to the 
drug solubility in the vehicle at 32°C. 
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3. Results 
 
3.1 Physico-chemical characterization of (RS)-PR, (S)-PR and their salts 
The main physico-chemical characteristics of (RS)-PR, (S)-PR and their salts are summarized 
in Table 1. The melting temperatures and the fusion enthalpies of (S)-PR-Ol and (S)-PR-Bz 
resulted significantly lower than the corresponding racemates suggesting that the latter are 
racemic compounds as the free base [6]. 
The apparent partition coefficients were not strongly affected by the type of counter ion. As 
expected, PR-Bz exhibited a higher solubility in saline solution and a lower solubility in 
mineral oil with respect to PR. PR-Ol presented the highest solubility in mineral oil. The 
solubility of PR-Ol in saline solution resulted difficult to be determined due to poor data 
reproducibility. Indeed, the solution cooled down from 60°C to 32°C resulted cloudy. 
Moreover, the filtrated solution returned cloudy in short time suggesting that the system was 
supersaturated. The same behaviour was observed dissolving PR-Ol at room temperature 
without the preliminary thermal treatment. When solutions at different concentrations were 
prepared, cloudiness was visually observed at concentration up to 50 µg/mL. Considering that 
the oleate determined a slight increase of the Log P, it is reasonable to hypothesize that, due to 
the high lipophilicity of the counter ion, the ionized propranolol and the oleate formed ion 
pairs which associate to form aggregates or micelles up to a certain concentration. Therefore, 
the critical micellar concentration (CMC) for (RS)-PR-Ol and (S)- PR-Ol was assessed. 
Throughout this work, the term CMC and micelles were used according to the current 
definition in surfactants, even though it is not clear if the micelles were really formed in the 
present systems. The prepared solutions/dispersions were assayed and micelles with a mean 
diameter of about 4±2 µm were measured at 20 µg/mL concentrations, independently of (RS)-
PROl or (S)-PR-Ol. In both the cases, the mean diameter increased increasing the drug 
concentration and the number of micelles remained at about 70,000 until the (RS)-PR-Ol or 
(S)-PR-Ol concentrations were lower than 50 µg/mL. Up to this concentration, the particle 
number increased to 300,000 justifying the cloudy aspect. The concentration at 20 µg/mL was 
considered the CMC for (RS)-PR-Ol or (S)-PR-Ol and it was assumed as the solubility of the 
(RS)-PR-Ol and (S)-PR-Ol at 23°C. 
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Table 1 - Physico-chemical properties of the compounds.  
     Solubility 
 
MW 
(Da) 
Tm 
(°C) 
DH 
(J/g) 
Log P 
Saline 
solution 
(mg/mL) 
Mineral  
oil 
(mg/mL) 
(RS)-PR 259.3 92.09±0.30 158.60±4.32 1.00±0.1 0.189 1.321 
(S)-PR 259.3 70.92±0.11 130.15±5.30 0.97±0.01 0.432 3.111 
(RS)-PR-Bz 318.5 142.45±0.09 123.80±2.40 1.07±0.00 4.430 0.065 
(S)-PR-Bz 318.5 112.99±0.23 103.70±0.85 1.06±0.00 9.560 0.118 
(RS)-PR-Ol 541.8 52.35±0.08 80.53±0.54 1.25±0.01 0.020* 3.930 
(S)-PR-Ol 541.8 35.75±0.01 62.04±2.04 1.28±0.01 0.020* 5.874 
*Extrapolated value by light scattering at 23°C 
 
3.2 In vitro human skin permeation 
The cumulative amounts of racemates and S-enantiomers permeated in 24 h through the SCE 
obtained from the two vehicles are shown in Figure 1. Independently of the vehicle and the 
use of racemates or enantiomers, the Jmax followed the rank order PR>PR-Ol>PR-Bz (Table 
2). 
The pKp of (S)-PR-Ol and (RS)-PR-Ol vehicled in saline solution were not calculated since the 
effective solubility of these compounds at 32°C was not determinable. In the other cases, 
independently of the use of the pure enantiomer or racemate, the permeability coefficients 
showed a strong dependence on both the counter ion and vehicle. When the saline solution 
was used, the values of Kp for PR resulted about 4 order of magnitude higher than those 
calculated for PR-Bz (Table 2). In mineral oil the following rank order of Kp was recorded 
PR-Ol > PR-Bz > PR (Table 2). 
As far as the skin permeability of the racemates with respect to the S-enantiomers is 
concerned, Jmax resulted highest when the pure enantiomer was used in agreement with the 
MTMT concept described by Toitou and co-workers [6], with the exception of the couple (S)-
PR-Ol and (RS)-PR-Ol vehicled in saline solution where, despite the lower Tm of the racemate 
(Table 1), the two fluxes resulted not statistically different (Table 2). 
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Figure 1 - Propranolol skin permeation profiles obtained using [A] saline solution or [B] 
mineral oil as vehicles.  
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Table 2 - Skin permeability data.  
 
Jmax 
(µg/cm2xh) 
Permeated amount after 
24h 
(µg/cm2) 
pKp 
 
Saline 
solution 
Mineral  
oil 
Saline 
solution 
Mineral  
oil 
Saline 
solution 
Mineral  
oil 
(RS)-PR 18.0±5.1 24.2±4.7 397±87 497±98 2.387±0.269 4.011±0.201 
(S)-PR 44.7±5.1 41.9±1.5 1015±94 907±145 2.274±0.117 4.307±0.03 
(RS)-PR-Bz 1.7±0.2 1.6±0.3 30±4 30±5 7.469±1.333 4.150±0.716 
(S)-PR-Bz 3.0±0.4 2.9±0.7 53±8 60±16 8.064±0.134 3.775±0.402 
(RS)-PR-Ol 7.0±1.4 7.3±1.4 162±25 171±38 -* 6.298±0.189 
(S)-PR-Ol 6.2±0.9 11.1±1.7 134±44 246±41 -* 6.276±0.153 
*non-calculable 
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4. Discussion 
 
The permeation of PR through the human stratum corneum is discussed focusing the attention 
on the three different variables, namely counter-ion, vehicle and chirality, which are mutually 
interfering on passive diffusion process of PR. 
 
4.1 Effect of the counter ion 
The total flux (Jtot) of a ionisable drug through the human epidermis from an aqueous solution 
is the result of the diffusion of different species. The transport properties can be described by 
the following equation: 
 
Jtot = Kp (union)* c(union) + Kp (ion)* c(ion)        (2) 
 
where Kp (union) and Kp (ion) are the permeability coefficients of the unionized and ionized 
species and c(union) and c(ion) are the relative concentrations in the vehicle [15]. 
In the case of PR-Bz, in the receiver medium the amounts of PR and Bz recovered were non-
stoichiometric. The ratio between the concentrations of benzoate and protonated propranolol 
PR(ion) in the receiver medium after 24 h was higher than 4 (data not shown) indicating that 
the ion pairs were not significantly involved in the diffusion process. Therefore, it is 
reasonable to assume that the PR(ion) is the main diffusant when the PR-Bz is vehicled in 
saline solution. 
In the case of PR, the ionized and unionized species in the saline solution were in equilibrium 
and Jtot was the result of the diffusion of both permeant species. Assuming Kp of (RS)-PR-Bz 
and (S)-PR-Bz as Kp (ion) of (RS)-PR(ion) and (S)-PR(ion), the extrapolated Kp (union) resulted about 
0.2 cm/h for both (RS)-PR and (S)-PR and the Kp(union) / Kp(ion) ratio was higher than 600 
confirming that, according to the stratum corneum hydrophobic characteristics, the unionized 
form is the main species involved in the permeation through the skin. Jmax determined using 
PR-Ol resulted intermediate between PR and PR-Bz indicating that a third species is involved 
in the diffusion through the skin. Indeed, on the bases of the behaviour of this salt in saline 
solution it is reasonable to think that the main species involved in the diffusion is the ion pair 
with oleate, even if the oleate was not detectable in the receiver medium. When the mineral 
oil was used as a vehicle, the calculated pKp value for PR and PR-Bz resulted not statistically 
different (p=0.800) indicating that the species involved in the permeation of PR-Bz were 
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different with respect to saline solution. Due to the low dielectric costant of mineral oil it’s 
reasonable to hypothetize that also PR-Bz associated to form a ion pair. In fact, the 
micromoles of PR and Bz recovered in the receiver medium at the end of the experiment were 
not statistically different both in the case of racemate and S-enantiomer (p>0.500) suggesting 
that PR-Bz permeates through the skin as ion pair. The association of PR with the two 
selected contra-ions could also justify the different pKp values obtained for PR-Ol and PR-Bz: 
the former exhibited an higher Jmax (Table 2) due to the higher solubility in mineral oil (Table 
1); the latter exhibited a lower pKp probably due to the lower Mw of the ion pair. 
The differences in solubility in both saline solution and mineral oil measured for each type of 
compound did not seem strongly to influence Jmax with the exception of (S)-PR-Ol. Indeed, 
while Jmax determined in saline solution and mineral oil of all tested substances were not 
statistically different (p>0.05), Jmax determined in mineral oil for (S)-PR-Ol resulted double 
than that obtained from saline solution (p>0.05). The behaviour could be due to the 
association of (S)-PR-Ol in micelles which reduces the drug solubility to that of the (RS)-PR-
Ol. The calculated pKp indicates that, in the case of the PR free base, the use of a vehicle with 
a high dielectric constant, such as the saline solution, permitted to obtain a permeability 
coefficient two orders of magnitude higher than that calculated for the mineral oil (Table 2). 
This result was unexpected since PR was more soluble in mineral oil than in water and the 
ionized form of PR in the saline solution did not significantly contribute to the flux of the 
drug. Therefore, the results suggested that water, that is a well-known skin enhancer [16], 
significantly increased the diffusion coefficient of the unionized PR through the human 
epidermis. Such statement is also in agreement with the influence of the vehicle on PR-Bz. In 
this case, when the drug is completely ionized, pKp in mineral oil resulted halved with respect 
to pKp in saline solution suggesting that water did not enhance the diffusion of the ionized 
form through the skin. On the contrary, the low dielectric constant value of the mineral oil 
promoted the ion pair formation between the ionized propranolol and benzoate and, therefore, 
the permeation of a non-charged species. This hypothesis could justify the same order of 
magnitude of pKp for PR and PR-Bz in mineral oil. 
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4.3 Skin permability of the PR racemates and the S-enantiomers 
When the racemic compounds were used, the concentrations of S-enantiomer and R-
enantiomer in the receiver medium after 24 h resulted non-statistically different (p>0.73) 
indicating that, in the selected experimental condition, the permeation of the drug through the 
skin was not influenced by the stereochemistry, but only by differences in physicochemical 
properties between enantiomers and racemates. 
According to the MTMT concept, both Jmax of racemates vehicled in saline solution or mineral 
oil resulted lower than those of the corresponding S-enantiomers. The only exception is the 
case of (RS)-PR-Ol and (S)-PR-Ol vehicled in saline solution since non-statistically different 
Jmax were calculated (p=0.86). This anomalous result can be easily explained considering the 
behaviour of PR-Ol in saline solution: the effective concentration, and therefore the 
thermodynamic activity, of (RS)-PR-Ol and (S)-PR-Ol resulted very similar and justified the 
overlapped skin permeation profiles. 
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5. Conclusions 
 
The ionic species of the permeant, which was deeply affected by the counter ion, appeared the 
main factor controlling the diffusion process of propranolol through human skin. More 
specifically, the following final remarks can be drawn. Generally speaking and confirming the 
literature data, the unionized form of propranolol exhibited the best skin permeability. When 
propranolol base was used, water was demonstrated to behave better than the mineral oil; in 
the other cases, its enhancing ability is probably overcome by thermodynamic effects of 
stabilization of the solute in the donor phase, thus minimizing and evening out its diffusion 
toward the stratum corneum. Finally, the MTMT concept appears a too simple approach for 
estimating differences between the racemate and the enantiomers if the solvent has an 
unexpected role in influencing the association and/or the aggregation of the solutes, as in the 
case of PR-Ol. 
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1. Introduction  
 
Propranolol is a chiral β-adrenergic blocker which undergoes to extensive first-pass hepatic 
metabolism and exhibits suitable phisico-chemical characteristics for transdermal delivery [1]. 
In humans, its biological activity is largely associated to a (S)-enantiomer, about 100 times 
more potent than the (R)-enantiomer [2]. 
In this work a formulation study of a monolayer patch loaded by propranolol was performed 
in order to evaluate the effects of the matrix composition in terms of polymer and enhancer 
type on the skin permeability of the drug. According to the results obtained in a previous 
work, propranolol in its basic form was used[3]. 
Since physicochemical properties and thermodynamic activity of the (S)-enantiomer are 
different from these of the racemate, the influence of the chirality on propranolol skin 
permeation was also studied. 
N-methyl pirrolidone was chosen as enhancer on the basis of a preliminary in vitro skin 
permeation study performed on a selection of four suitable enhancers (butyl-oleate, ethyl-
oleate, dimethyl sulfoxide and N-methyl pyrrolidone). Methacrylic, siliconic or styrenic 
polymer were selected as pressure sensitive adhesives. 
The patches were prepared by casting technique, and characterized in terms of drug content, 
crystallization time and dissolution profile. The in vitro skin permeability was determine by 
Franz cell method. The local skin toxicity of the formulation containing (S)-propranolol was 
in vivo assessed by the skin irritation test EN ISO 10993-10:2002, using rabbits as model. 
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2. Materials and methods 
 
2.1 Materials 
(RS)-Propranolol, (RS)-PR (S.I.M.S., Italy); Ethyl-oleate (ET-OL) (Gaylord Chemical 
Corporation, Louisiane); Butyl-oleate (BU-OL) (Gaylord Chemical Corporation, Louisiane); 
Dimethyl sulfoxide (DMSO) (Gaylord Chemical Corporation, Louisiane); Acetyl Tributyl 
Citrate (ATBC) (Morflex, Greensboro North Caroline); Tributyl Citrate (TBC) (Morflex, 
Greensboro North Caroline); Eudragit E100 (EuE 100), (Röhm, Darmstadt, Germany); 
Eudragit NE 40D (EuNE 40D), (Röhm, Darmstadt, Germany); Roderm PA-0607 Acrylic 
adesive (Rohm and Haas Company, Philadelphia, USA); Bio-PSA 7-4301 Silicone Adhesive 
(Dow Corning Corporation, Michigan USA); Bio-PSA 7-4302 Silicone Adhesive (Dow 
Corning Corporation, Michigan, USA); Stirene-etilene/butilene-stirene (SEBS) (Polimeri 
Europa, Eni); N-methyl pyrrolidone (Sigma-Aldrich, S.r.l., Italy ); DURO-TAK 87-608A 
(National Starch & Chemical, USA); DURO-TAK_ 87-611A (National Starch & Chemical, 
USA); mineral oil (OV) (A.C.E.F. s.p.a., Piacenza, Italy); Backing layer: polyethylene 
membrane (Bouty, Italy). Release liner: silicon polyester (Bouty, Italy). 
All the solvents, unless specified, were of analytic grade. 
 
2.2 Solution preparation 
The solutions were prepared adding (RS)-PR as such or (RS)-PR solutions in the selected 
permeation enhancer to OV.  
The samples were stirred at 32±1 ºC for 24 h to obtain equilibrated solutions and filtrated 
before using. 
The composition of the solutions is shown in Table 2.1. 
 
Table 2.1 - Solution compositions (%w/v). 
Solution (RS)-PR  ET-OL BU-OL DMSO NMP OV 
S1 0.75 - - - - 99.25 
S2 2 10.00 - - - 88.00 
S3 2 - 10.00 - - 88.00 
S4 2 - - 10.00 - 88.00 
S5 2 - - - 10.00 88.00 
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2.3 Patch preparation  
The patches were prepared by using a laboratory-coating unit Mathis LTE-S(M) (Mathis, CH) 
equipped with a blade coater . The mixture was spread on the release liner at the constant rate 
of 1 m/min. The coating thickness was fixed at 300 µm or 550 µm in order to obtain a patch 
of thickness respectively of 50 µm or 150 µm . The systems were dried at 60° C for 20-25 
min, covered with the backing layer, sealed in an airtight container and stored at 25± 1 °C. 
The composition of the polymeric mixtures is reported in Table 2.2. 
 
Table 2.2 - Polymeric mixture compositions (%w/w). 
Mixtures 
Components 
M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 
(RS)-PR 3.40 3.47 2.02 2.02 2.20 3.05 2.61 3.07 3.07 2.88 4.65 
NMP 4.60 6.87 6.24 6.24 5.97 5.72 6.00 5.80 - 8.61 8.91 
DMSO - - - - - - - - 5.80 - - 
EuNE 40D - - - - - - 65.27 - - - - 
EuE 100 - - - - - 34.22 - - - - - 
BioPSA 7-4301 - - 91.74 - - - - - - - - 
BioPSA 7-4302 - - - 91.74 - - - - - - - 
Roderm PA-0607 92.00 - - - - - - - - - - 
Durotak 87608A - - - - 91.83 - - - - - - 
Durotak 87611A - - - - - - - 85.32 85.32 79.90 77.50 
SEBS * - 31.98 - - - - - - - - - 
TBC - - - - - - 26.11 - - - - 
ATBC - - - - - 15.90 - - - - - 
Aceton - - - - - 23.66 - - - - - 
Isopropanol - - - - - 2.81 - - - - - 
ethanol - - - - - 13.28 - - - - - 
Succinic acid - - - - - 1.36 - - - - - 
Tetrahydrofuran - 31.89 - - - - - 5.80 5.80 8.61 8.91 
Liquid paraffin - 25.73 - - - - - - - - - 
Antioxidant - 0.05 - - - - - - - - - 
SEBS* composition: TH2315 polymer (4.33 % w/w); TH2311 polymer (3.53 % w/w), regalite 1100 (29.73 % 
w/w), tetrahydrofuran (33.33 % w/w), liquid paraffin (29.00 % w/w), antioxidant (0.066 % w/w). 
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2.4 Drug content 
The drug content of formulations P7 was determined by using the A method, while the drug 
content of formulations P8-P11 was determined by using the B method. 
 
A Method - A patch sample of 2.54 cm2 was dissolved in 20 mL of methanol and diluted 1:10 
in mobile phase (HPLC grade). The solutions were filtered (Durapore membrane, pore size 
0.45 µm; Millex GV, Millipore Corporation, USA) and assayed by HPLC with the method 
reported in the section 2.7. Each value represent the mean of three determinations. 
 
B Method - A patch sample of 2.54 cm2 was dissolved in 10 mL of toluene . The (RS)-PR 
solubilised in toluene was extracted by three successive extractions with 15 mL of water 
acidified to pH 2.5 using a separating funnel. 
The aqueous solution was filtered (Durapore membrane, pore size 0.45 µm; Millex GV, 
Millipore Corporation, USA) and assayed by HPLC with the method reported in the section 
2.7. Each value represents the mean of three determinations. 
 
2.5 Ex vivo skin permeation studies 
The skin used in the transdermal permeation studies was obtained from the abdomen of three 
different patients who underwent cosmetic surgery. The full-thickness skin was sealed in 
evacuated plastic bags and frozen at -20°C within 24 h after removal. Prior to preparation, the 
skin was de-frozen to room temperature, and the excess fat was carefully removed. The skin 
sections were cut into squares and, after immersing the skin in water at 60°C for 1 min, the 
human epidermis was gently separated from the remaining tissue with forceps. Prior to 
experimental use, the sample was carefully inspected for any defects before mounting them 
onto the Franz diffusion cells with the epidermis facing upwards and the stratum corneous 
side in contact with the sample. In the case of saturated solution, the upper and lower parts of 
the Franz cell were sealed with Parafilm® and fastened together by means of a clamp, with the 
human epidermis specimen acting as a seal between the donor and receptor compartments. 
The donor compartment was filled by 0.5 mL of the solution and closed. In the case of the 
medicated patch, a sample of 2.54 cm2 was applied to the diffusion cell as donor phase before 
sealing the two compartments. The experiments were performed after 3 weeks of storage. The 
used vertical cells had a wider column than the original Franz-type diffusion cell, and the 
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bowl shape was removed. They had a diffusion area of 0.636 cm2 and a 5 mL (approx.) 
receptor compartment. The receiver volume of each cell was individually calibrated. The 
receiver medium, constituted of physiologic solution, was continuously stirred with a small 
magnetic bar and thermostated at 37 ± 1 °C, so that the skin surface temperature was 32 ± 1 
°C. At predetermined times, 0.2 mL samples were withdrawn from the receiver compartment 
and replaced with fresh receiver medium. Sink conditions were maintained throughout the 
experiments. Samples were analyzed by HPLC according to the method described in the 
section 2.7. 
 
2.5.1 Data analysis 
The cumulative amount permeated through the skin per unit area was calculated from the 
concentration of each substance in the receiving medium and plotted as a function of time. 
The steady flux (Jmax) was determined as the slope of the linear portion of the plot. The 
permeability coefficient was calculated according to Fick’s first law of diffusion (equation 1): 
S
J
K P
max=  (1) 
where Kp (cm/h) is the permeability coefficient, Jmax (µg/cm2 per h) is the flux obtained with 
the saturated solution and S is the drug donor concentration (µg/cm3), corresponding to the 
drug solubility in the vehicle at 32 °C. 
 
2.6 In vitro release studies 
The dissolution test was performed using an apparatus SR8 PLUS Dissolution test station 
(Hanson Research, CA, USA) according to the Disk Method of the European Pharmacopoeia 
(Ph. Eur. VI Ed.). A patch sample of 12.56 cm2 was placed flat on the disk with the release 
surface facing up. The back of the plaster was attached on the disk by using a cyanoacrylate 
adhesive (super attak®). The experiment was performed by using 500 mL of deionised water as 
dissolution medium maintained at 32 0.5 °C and stirred at 50 rpm. At fixed intervals, the 
dissolved amount of (RS)-PR released from the plasters was determined by HPLC method 
described in the section 2.7 The results are expressed as mean of three samples. 
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The release rate constant was calculated according to Higuchi equation (2): 
 
Mt/M∞= kt0,5 (2) 
 
where Mt is the released amount of the drug in the time, M∞ is the initial amount of active 
ingredient contained in the patch and k is the release rate constant (h-1). 
 
2.7 Drug assay 
The concentration of (RS)-PR in the medium was determined by HPLC assay (HP 1100, 
Chemstations, Agilent Technologies, USA). A 20 µL sample was injected at 25 ºC on a C18 
reverse-phase column (Bondclone C18, 10 µm, 3.9 x 300 mm, Phenomenex, USA). The 
wavelength was set at 225 nm. The composition of the eluent was acetonitrile/0.2% 
phosphoric acid 30/70 v/v, the flow rate was 1.0 mL/min and the temperature was 25°C. 
Three standard calibration curves (0.005-5 µg/mL; 1-40 µg/mL; 10-200 µg/mL) were used. 
The limit of quantification was 0.004 µg/mL. Resolution from the background noise was 
adequate at this level. The calibration curves were prepared by using known concentrations of 
(RS)-PR in the mobile phase. 
 
2.8 Monitoring crystal formation 
Appearance of drug crystals in the patches was monitored visually and microscopically 
(Axioscope, Zeiss, G) throughout an area of 10 cm2. The monitoring time intervals were daily 
in the first 2 weeks and then bi-weekly over a six-month period. 
 
2.9 Skin irritation test 
The local skin toxicity was assessed by the skin irritation test EN ISO 10993-10:2002. The 
test was performed by Biolab S.p.A (Vimodrone -Mi- Italy). 
Three male albino rabbits, bred New Zealend, weighing 3100-3190 g were used. 
The back’s right caudal and left cranial area of each tested animal were treated 
with the examined substance. As cross control, the symmetric areas of each animal (right 
cranial and left tail areas) were treated by application of a semi-occlusive gauze moistened 
with non irritant saline solution. 
The possible reactions in the treated areas were compared with those in the control areas.  
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Twenty-four hours before the test, the fur was removed from an area approximately 240 cm2 
wide by clipping and shaving the dorsal and flank zones of the animals. An area of the back, 
about 6 cm2 wide, was designed for the application of the test sample. 
25 x 25 mm of the test substance were applied directly to the skin on cranial site of each 
rabbit. The application sites were covered with non occlusive dressing and the trunk of the 
animal was wrapped with a semi-occlusive bandage. 
The patches were removed 4 hours after the application. 
Reactions were evaluated following the removal of the patches and were evaluated again at 
24, 48 and 72 hours after exposure. 
Skin irritation was scored and recorded according to the scores reported in the Table 2.3 
 
Table 2.3 - Grading values of skin reactions 
Formation of erythema and eschar Score 
no erythema 0 
very slight erythema (barely perceptible) 1 
well-defined erythema 2 
moderate erythema 3 
severe erythema (beet redness with slight eschar 
formation; injuries in depth) 
4 
Formation of edema Score 
no edema 0 
very slight edema (barely perceptible) 1 
Slight edema (edges of area well defined by definite 
raising) 
2 
moderate edema (raised approximately 1 mm) 3 
severe edema (raised more than 1 mm and extending 
beyond the area of exposure) 
4 
 
For acute exposure, the Primary Irritation Index (PII) was determined as follows. For each 
animal, the Primary Irritation Scores for the test substance for both erythema and edema at 
each time specified were added together and divided by the total number of observations. 
When vehicle controls were used, the Primary Irritation Score for the vehicle controls was 
calculated and subtracted from the score for the test substance to obtain the Primary Irritation 
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Score. Only 24 hours, 48 hours and 72 hours observations were used for calculations. 
Observations made prior to dosing or after 72 hours, to monitor recovery, were not used in the 
determination. The scores for each animal were added and the total was divided by number of 
animals. This value is the Primary Irritation Index. Number and description in Table 2.4 
characterise the Primary Irritation Index: 
 
Table 2.4 - Irritation category  
Response category Mean score 
negligible 0.0 to 0.4 
sligh 0.5 to 1.9  
moderate 2.0 to 4.9 
severe 5.0 to 8.0 
 
2.10 ATR-FTIR spectroscopy 
Hydrated epidermal sheet was dipped into pure OV or NMP/OV 10/90 w/w for 6 h. After 
treatment, each piece was wiped with filter paper and left to dry for few minutes. FT-IR 
spectra of control and all treated pieces were recorder on Spectrum One (Perkin Elmer, USA) 
spectrometer. The spectra were recorded in triplicate on the ATR accessory of the FT-IR 
spectrometer equipped with a diamond crystal with following acquisition parameters: 
resolution of 4 cm-1 and number of 128 scans. The wavenumber of the peak as well as hidden 
peaks are detected by second derivative minima and the areas of the deconvoluted peak were 
calculated using the peakfit software. 
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3. Results 
 
3.1 Identification of the permeation enhancer 
In order to increase the solubility of (RS)-PR in the adhesive matrix, compatible co-solvents 
were considered. The attention was focused on the effects of dimethyl sulfoxide (DMSO), N-
methyl pyrrolidone (NMP), butyl-oleate and ethyl-oleate since they can also play a 
fundamental role as permeation enhancers. 
Considering the good ability of (RS)-PR to permeate the skin when dissolved in OV [3], this 
solvent was selected as donor phase to evaluate the enhancement activity of the considered 
co-solvents by using the Franz cells method. 
The addition of these cosolvents dramatically increased the drug solubility in liquid paraffin. 
Therefore, the (RS)-PR concentration in the donor phase was fixed at the 2% w/w. 
The skin permeability test was performed by using skin from two different donors of human 
epidermis. The (RS)-PR permeability from solutions S1, S2 and S3 was determined using the 
first donor (a). The skin of second donor (b) was used to test the solution S4, S5 and to retest 
the solution S1, employed as reference to compare data from different skins.  
The permeability data were summarized in Table 3.1 and the skin permeation profile reported 
in Fig. 3.1 and 3.2. 
 
Table 3.1 - Permeated amounts after 24 h (PA24) and fluxes (Jmax) of (RS)-PR from solutions 
(mean ± dev.st., n=3). 
Solution Cosolvent 
Human skin 
donor 
PA24 
(µg/cm2) 
Jmax 
(µg/cm2/h) 
S1 - a 549.11±60.93 23.56±2.62 
S1 - b 386.65±128.19 17.17±5.91 
S2 Ethyl-oleate a 524.43±239.56 22.85±11.21 
S3 Butyl-oleate a 610.89±207.50 25.86±7.68 
S4 Dimetyl sulfoxide b 401.90±93.41 17.56±3.89 
S5 N-methyl pyrrolidon b 763.24±30.00 33.10±1.32 
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Fig 3.1 - (RS)-PR ex vivo skin permeation profile from solutions S1, S2, S3 (mean ± st dev, 
n=3). 
 
 
Fig 3.2 - (RS)-PR ex vivo skin permeation profile from solutions S1, S4, S5 (mean ± st dev, 
n=3). 
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DMSO, butyl-oleate and ethyl-oleate were not effective in promoting the drug permeation. 
The permeated amounts of (RS)-PR from solutions S2, S3 and S4 were not significantly 
different (p > 0.05) with respect to those obtained using the reference solution S1, namely 
(RS)-PR at lower concentration vehicled in OV (Table 3.1). The addition of NMP allowed to 
enhance the (RS)-PR permeability and double the flux (Table 3.1).  
In order to clarify the enhancement mechanism of NMP, its effect on the human stratum 
corneum was investigated by FTIR spectroscopy. 
The spectra of the human epidermis in OV or NMP/OV 10/90 w/w recorded after 6 h and 24h 
of incubation are exemplified in Figure 3.3 and main bands are reported in Table 3.2.  
 
 
Figure 3.3 - Spectra of the human epidermis in OV or NMP/OV 10/90 w/w  
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Table 3.2 - Assignment of the main band recorded in the ATR-FTIR spectra 
Asimmetric 
CH2 
Simmetric 
CH2 
Amide I Amide II Ester C=O Time 
(h) 
Solvent 
cm-1 height cm-1 height cm-1 height cm-1 height cm-1 Height
6 OV 2921 0,12 2851 0,08 1651 0,06 1546 0,05 1745 0,02 
 NMP/OV 2922 0,14 2852 0,09 1651 0,04 1546 0,03 1745 0,02 
24 OV 2918 0,18 2850 0,12 1651 0,25 1547 0,20 1743 0,02 
 NMP/OV 2922 0,18 2851 0,11 1651 0,21 1548 0,16 1746 0,02 
 
The main bands of interest were in the CHx and C=O stretching regions at 2950-2800 cm-1 
and 1750-1700 cm-1 assigned to the lipidic network of the stratum corneum [4] and the amide 
I band at about 1650 cm-1. It is well known that skin penetration enhancers which perturb the 
stratum corneum determine shift or modification of the intensity of such bands [4,5]. 
Therefore, to better elucidate the interference of NMP with stratum corneum the bands were 
deconvoluted. The analyses of the two spectra revealed that neither the bands in the CHx 
region nor those obtained by deconvolution of the amide I were significantly modified by the 
penetration of NMP into the stratum corneum (Table 3.3 and Table 3.4).  
 
Table 3.3 - Assignment of the hidden bands revealed by deconvolution of the spectra in the 
CHx region recorded after 6 h of incubation. 
Epidermis treated by MO Epidermis treated by OV/NMP 
Assignment Peak 
(cm-1) 
Area % Area 
Peak 
(cm-1) 
Area % Area 
CH3 asymmetric 2953 1.492 19.0 2953 1.860 19.5 
CH3 symmetric 2921 3.003 38.3 2921 3.445 36.2 
not assigned 2896 1.144 14.6 2897 1.454 15.2 
CH2 asymmetric 2875 0.426 5.4 2876 0.536 5.6 
CH2 symmetric 2853 1.790 22.7 2853 2.245 23.5 
 Total 7.856 100.00 Total 9.540 100.00 
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Table 3.4 - Assignment of the hidden bands revealed by deconvolution of the spectra in the 
amide I region recorded after 6 h of incubation. 
OV OV/NMP 
Assignment Peak 
(cm-1) 
Area % Area 
Peak 
(cm-1) 
Area % Area 
1631 0.407 17.9 1628 0.307 19.1 β-sheet 
1642 0.414 18.2 1642 0.319 20.0 
Random coil 1649 0.414 18.2 1650 0.295 18.4 
α helices 1660 0.484 21.2 1660 0.336 21.0 
1675 0.267 11.7 1674 0.214 13.3 Antiparallel β-sheet 
and/or β-turn 1686 0.065 2.9 1685 0.047 2.9 
 Total 2.280 100.000 Total 1.599 100.000 
 
Nevertheless, the ratio between the amide I and the stretching vibration of C=O decreased 
indicating that the use of NMP enhanced the partial extraction of the aliphatic lipids of the 
stratum corneum due to the incubation of the human epidermis with OV. Indeed, the ratio of 
the height of the symmetric CH2 stretching vibration and the amide I stretching vibration 
significantly decreased either after 6 h and 12 h of incubation with respect to the samples 
treated only by OV. 
The second derivative performed in the C=O stretching band region revealed a hidden peak at 
1705 cm-1 that can be attributed to the presence of NMP into the epidermis. Indeed the spectra 
of a NMP/OV 10/90 w/w mixture exhibited a peak at 1705 cm-1 clearly attributable to NMP 
since this peak was clearly detectable in the spectra recorded using the pure NMP or 
OV/NMP 90/10 mixture.  
No other change in the spectra were noticeable confirming that NMP was unable to modify 
the fluidity of the lipidic network of the stratum corneum.  
Considering that NMP was able to permeate the skin, as exemplified in Fig 3.4, its flux across 
the stratum corneum could improve the transport of formulation solutes by a co-transport 
mechanism and the drug-NMP interactions may have a critical role in the efficacy of NMP as 
skin permeation enhancer. 
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Fig 3.4 - HPLC profile of receiver phase of a Franz’s cell at 24 h using S5 as donor phase. 
 
3.3 Selection of the adhesive matrix 
On the bases of the obtained results, NMP was chosen as permeation enhancer. 
As it was demonstrated that (RS)-PR was soluble in NMP at ratio of 1:2 (%, w/w) at 25 °C, 
polymeric mixtures can only contain 10 % NMP and amounts of (RS)-PR which did not 
exceed about 5%.  
The selection of adhesive matrix was made evaluating (a) the compatibility of the solution 
containing NMP and (RS)-PR with the polymers used to obtain the polymeric matrices and 
(b) the appearance of drug crystals in the patch after casting of the polymeric mixtures. 
The results were shoved in Table 3.5. 
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Table 3.5 - Compatibility of the solution containing N-methyl pyrrolidon and (RS)-PR 
with the polymers used to obtain the polymeric matrices and appearance of drug crystals 
in the plasters after casting of the corresponding polymeric matrices. 
Polymeric Mixtures Type of Polymer Compatibility 
Drug crystal 
appareance 
M1 Roderm PA067 Yes Yes 
M2 SEBS Yes Yes 
M3 BIO-PSA 7-4301 No - 
M4 BIO-PSA 7-4302 Yes Yes 
M5 DURO-TACK 87-608A No - 
M6 Eudragit E 100 Yes Yes 
M7 Eudragit NE 40 D Yes No 
M8 DURO-TACK 87- 611A Yes No 
- The matrices incompatible with the solution containing N-methyl pyrrolidon and (RS)-PR have not been 
subjected to casting. 
 
The solution of PR in NMP was immiscible with the polymeric systems dispersed in heptane. 
In fact, the addition of the solution in the mixture M3 and M5 caused the coacervation and 
precipitation of the polymers. 
M7 and M8 were the only two polymeric mixtures suitable to prepare patch, since no drug 
crystals appeared after casting. Table 3.6 shows the composition of the patches obtained by 
casting of M7 and M8 mixtures.  
 
 
Table 3.6 - Patch compositions (% w/w). 
Patch (RS)-Pr NMP Polymer 
P7 4.29 9.97 85.84 
P8 5.30 10.01 84.68 
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3.4 Patch characterization  
The skin permeability of PR vehicled in patches, was performed by using the same donor (b) 
previously used for the solution containing N-methyl pirrolidon (S5). 
In order to determine the enhancement activity of NMP, DMSO was used as a cosolvent in 
formulation P9 as it was demonstrated to be ineffective in promoting the skin permeability of 
(RS)-PR in solution. 
The data concerning the characterization and the skin permeability of the patches are 
summarized in Table 3. 7. 
 
Table 3.7 - Crystallization time, thickness, drug content and permeability data of patches 
(Permeated amounts after 48 h (PA48) and fluxes (Jmax)). 
- not determined 
 
 
Fig 3.5 - PR ex vivo skin permeation profile from P7, P8 and P9 patches (mean ± st dev, 
n=3). 
 
Patch 
Crystall. time 
(month) 
Thickness 
(µm) 
Drug content 
(µg/cm2) 
Jmax 
(µg/cm2/h) 
PA48 
(µg/cm2) 
P7 >6 150 1036,9±4,7 11,7±1,6 529,3±77,1 
P8 6 150 847,2±4,7 11,5±0,9 539,3±42,3 
P9 - 150 900,4±39,2 11,5±0,2 539,8±12,1 
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The flux of (RS)-PR from all formulations resulted comparable (Table 3.7, p > 0.05) and 
much lower than that obtained from the solution S5. The overlapping of permeation profiles 
of (RS)-PR for the styrene matrices containing NMP (P8) and DMSO (P9) indicated that 
NMP was ineffective in promoting the permeation of (RS)-PR contained in the patch. Since 
NMP was not detected neither in the receiving phase of Franz cell nor in the dissolution 
medium, the lack of enhancement activity was due to the fact that NMP was not released from 
the polymeric matrix. 
As far as the dissolution test is concerned (Fig 3.6), the release rate constants of (RS)-PR 
calculated according to the Higuchi’s equation were 0.16 and 0.12 for P7 and P8, 
respectively.  
While the (RS)-PR amount permeated by the methacrylic patch P7 followed a linear kinetic 
up to the 55th hour, after which the curve reached a plateau, the styrenic patch P8, with a 
slower release rate constant than P7, showed a linear permeation kinetic throughout the 
period. 
 
 
Fig 3.6 - In vitro release profile of (RS)-PR from Form. P7 and P8 (mean ± st dev, n=3). 
 
Although both patches were able to ensure a constant permeation flux for a period of time of 
at least 48 h, the formulation P8 resulted unsuitable for the transdermal delivery of (RS)-PR 
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because of the appearance of crystals of active substance after a storage period of 6 month at 
25 ° C. 
In order to evaluate the influence of the chirality of PR on the permeation through the skin, 
two patches containing the S-enantiomer ((S)-P7) and the racemate ((RS)-P7) were prepared 
using the formulation P7. The skin permeability data (Table 3.8) revealed that no differences 
were noticeable between the enantiomer and the racemate. Indeed, both the fluxes and the 
amounts permeated after 24 h of (S)-PR resulted not statistically different from those 
determined using the identical formulation containing the racemate (p = 0.13). 
 
Table 3.8 - Thickness, drug content and permeability data of (RS)-P7 and (S)-P7 patches 
(Permeated amounts after 24 h (PA24) and fluxes (Jmax)). 
Patch 
Thickness 
(µm) 
Drug content 
(µg/cm2) 
Jmax 
(µg/cm2/h) 
PA24 
(µg/cm2) 
(RS)-P7 50 153.0±15.1 1.8±0.1 40.5±2.2 
(S)-P7 50 194.2±2.1 2.5±0.5 55.7±11.0 
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Fig 3.7 - Ex vivo skin permeation profile of PR contained in (RS)-P7 and (S)-P7 patches 
(mean ± st dev, n=3). 
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These experimental permeation data were not in agreement with the melting temperature-
membrane transport (MTMT) concept [1,6], based on the interdependence of the melting 
temperature and the membrane transport behaviour of a chiral penetrant.  
Even if it was not possible to experimentally determine the solubility of (RS)-PR and (S)-PR 
in the patch matrices, the solubility of (RS)-PR should be lower with respect to that of (S)-PR 
on the bases of their thermal data (the melting temperatures are 92.09±0.3 °C and 70.92±0.11 
°C for (RS)-PR and (S)-PR respectively). As a consequence, considering that the 
concentrations of the pure enantiomer and racemate are the same, the thermodynamic activity 
of (S)-PR should be lower than that of (RS)-PR and, therefore, the (S)-PR flux should result 
lower than that of (RS)-PR. The lack of differences in the Jmax,S and Jmax,RS could be justified 
supposing that the drug thermodynamic activity in the adhesive matrix was not the main 
limiting step in the permeation process, but that the skin absorption of PR was probably 
limited by its diffusivity in the adhesive matrix. 
The area of patch P7, useful to obtain an effective plasmatic concentration of PR, was 
estimated to be about 150 cm2, calculated according to the following equation (3): 
 
Css = J A/Cl   (3) 
 
where Css is the concentration at the steady state (25 µg/L), J is the permeation flux of the 
patch (11,7 µg/cm2/h) and Cl is the PR clearance (70 µg/h). 
Considering that no differences were noticeable between the enantiomer and the racemate in 
the PR skin permeability, the area of patch P7 could be significant reduced loading (S)-PR, 
which is 100 times more potent than the R-enantiomer. 
A further reduction of area could be obtained by increasing the concentration of PR in the 
patch using a greater amount of NMP. Although not released from patch, an increase of NMP 
would allow the solubilisation of a greater amount of PR, increasing the thermodynamic 
activity of the drug in the matrix. 
As several works refer of skin irritation produced by β-blockers, typically when base forms 
were used [7, 8], the local skin toxicity of the formulation P7 containing (S)-PR was 
investigated using rabbits as animal model and the corresponding placebo patch as a control. 
The base form, which is more lipophilic, can easily permeate across the stratum corneum, but 
could not easily diffuse into the more hydrophilic epidermis and, thus, could form a depot in 
the skin, which in turn could become a chemical irritant leading to erythema and edema [9].  
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No animal showed signs of erythema and edema at the end of the experiment and the primary 
irritation index was 0.0, indicating that the patch containing (S)-PR was not irritant for the 
skin. This can be due to the ability of the patch to control the release of PR over a prolonged 
period of time, thus preventing the formation of a skin depot of the drug. 
In conclusion, was demonstrated the feasibility to administrate PR by transdermal patches. In 
particular the methacrylic matrix permitted to obtain a patch non-irritating to the skin, able to 
ensure a constant permeation flux of PR for a time period of 48 h.  
The results also allowed to underline that NMP seems to enhance the permeation of polar 
drug by a co-transport mechanism, rather than a reversible alteration of the stratum corneum 
and that the vehicle can play a key role on its efficacy.  
Indeed, the data generated by using transdermal patches, in agreement with those reported in 
literature for captopril [10], showed that the vehicle can influence the enhancement efficacy 
of NMP by dramatically affecting the partition from the dosage form to the stratum corneum. 
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Effect of drug chirality 
and supersaturation 
on the skin permeability of Ibuprofen
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1. Introduction 
 
Ibuprofen (IB) is a chiral non-steroidal anti-inflammatory drug widely used in the treatment of 
musculoskeletal injuries. Even if the pharmacological activity of this drug resides in the S-
enantiomer, IB is usually administrated as racemate (RS-IB) since an extensive bioconversion 
of the R-enantioner to S-enantiomer occurs after oral administration [1]. The topical 
administration of IB allows the patients to have a faster pain relief in comparison to the oral 
route accompanied with low plasma concentration and thus low incidence of systemic side 
effects [2]. Nevertheless, the skin metabolism does not result in the chiral inversion of (R)- to 
(S)-ibuprofen (S-IB) [3] and therefore, the anti-inflammatory effect is due to an half of the 
administered dose. The selection of RS-IB or S-IB is not only related to the drug intrinsic 
pharmacological activity, but also to its physico-chemical properties. Indeed, the lower 
melting point of the stereoisomers of chiral compounds, the higher solubility in the vehicle 
and, consequently, the greater the flux through the skin [4]. The melting point of S-IB is about 
one third lower than the racemate and thus, it is expected that its flux through human skin is 
higher than that of the racemate. Nevertheless, to the best of our kwnoledge, the skin 
permeability through human skin of S-IB and RS-IB has been not compared. In addition the 
design of the dosage form plays an important role in topical drug delivery as the composition 
of the vehicle influences the partitioning and/or the diffusivity of the drug and hence the 
absolute delivered amount. As far as RS-IB is concerned, supersaturated solutions [5] as well 
as supersaturated medicated plasters resulted effective in the promotion of the drug skin 
permeation [6]. Such a plaster was developed by adding to a type of polydimethylsiloxane 
pressure sensitive adhesive (PSA) propylene glycol and a polyaminomethacrylate, namely 
Eudragit RL100, which resulted effective as anti-nucleation agents and therefore able to 
promote the physical stability of the supersaturated adhesive matrix. In the present work, the 
in vitro passive diffusion of S-IB and RS-IB through human epidermis was studied to evaluate 
the impact of drug chirality and vehicle on the permeation process. With this aim, S-IB and 
RS-IB saturated solutions and supersaturated plasters, prepared by using the same formulation 
proposed in a previous work [6], were used as vehicles. Furthermore, since the drug loading 
and drug/excipients ratio can play a key role in the thermodynamic activity of the drug in the 
adhesive matrix and therefore in its permeation through the skin, a formulative study was also 
carried out. 
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2. Materials and methods 
 
2.1 Materials 
S Ibuprofen, S-IB (Francis, I); RS ibuprofen, RS-IB, and propylene glycol, PG (ACEF, I); 
Eudragit RL100, EuRL (Rofarma, I);BIO-PSA 7-4602, B46 (Dow Corning, USA). Backing 
layer: Cotran 9715 membrane (3M, USA). Release liner: Scotchpak 1022 film (3M, USA). 
Brufen crema 10% m/m (Abbot SpA, I). 
All solvents unless specified were of analytical grade. 
 
2.2 Solubility determination 
The solubility of S-IB and RS-IB was determined in water at 32 ºC. The samples were stirred 
at 32±1 ºC for 72 h to obtain saturated solutions. The solute in excess was removed by 
filtration. The saturated solutions were opportunely diluted in water and then analyzed by the 
HPLC method described in the Section 2.7. The results are expressed as mean ± st dev (n=3). 
 
2.3 Thermal analysis 
DSC data were recorded by using a DSC 2010 TA (TA Instruments, USA). The samples were 
sealed in aluminum pans and heated in inert atmosphere (70 ml/min N2). The reference was 
an empty pan. The equipment was calibrated with an indium sample. Samples of S-IB or RS-
IB were scanned at 10 K/min from 30°C to 120°C under nitrogen purging (70 mL/min).  
 
2.4 Plaster preparation  
The plasters were prepared by using a laboratory-coating unit Mathis LTE-S(M) (Mathis, CH) 
equipped with a blade coater . The mixture was spread on the release liner at the constant rate 
of 1 m/min. The coating thickness was fixed at 300 µm. The systems were dried at 50 C for 
20 min, covered with the backing layer, sealed in an airtight container and stored at 25 1 °C. 
The final composition of the dried plaster matrices is reported in Table 1. 
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2.5 Drug content 
A plaster sample of 2.54 cm2 was dissolved in 20 mL of ethyl acetate and diluted in 10 ml of 
mobile phase (HPLC grade). The solutions were filtered (Durapore membrane, pore size 0.45 
µm; Millex GV, Millipore Corporation, USA) and assayed by HPLC with the method 
reported in the Section 2.7. Each value represents the mean of three determinations. 
 
2.6 In vitro release studies 
The dissolution test was performed using an apparatus SR8 PLUS Dissolution test station 
(Hanson Research, CA, USA) according to the Disk Method of the European Pharmacopoeia 
(Ph. Eur. VI Ed.). A plaster sample of 8.04 cm2 was placed flat on the disk with the release 
surface facing up. The back of the plaster was attached on the disk by using a cyanoacrylate 
adhesive. The experiment was performed by using 500 mL of phosphate buffer (pH 5.5) as 
dissolution medium maintained at 32±0.5 °C and stirred at 50 rpm. At fixed intervals, the 
dissolved amount of IB released from the plasters was spectrophotometrically determined at 
227 nm wavelength. The results are expressed as mean of three samples. 
 
2.7 Ex vivo human skin permeation studies 
The skin used in the transdermal permeation studies was obtained from the abdomen of three 
different patients who underwent cosmetic surgery. The full-thickness skin was sealed in 
evacuated plastic bags and frozen at -20°C within 24 h after removal. Prior to preparation, the 
skin was de-frozen to room temperature, and the excess fat was carefully removed. The skin 
sections were cut into squares and, after immersing the skin in water at 60°C for 1 min, the 
human epidermis was gently separated from the remaining tissue with forceps. Prior to 
experimental use, the sample was carefully inspected for any defects before mounting them 
onto the Franz diffusion cells with the epidermis facing upwards and the stratum corneous 
side in contact with the sample. In the case of saturated solution, the upper and lower parts of 
the Franz cell were sealed with Parafilm® and fastened together by means of a clamp, with the 
human epidermis specimen acting as a seal between the donor and receptor compartments 
and, therefore, the donor compartment was filled by 0.5 mL of the solution and closed. In the 
case of the medicated plasters, a sample of 2.54 cm2 was applied to the diffusion cell as donor 
phase before sealing the two compartments. The experiments were performed after 3 weeks of 
storage. The used vertical cells had a wider column than the original Franz-type diffusion cell, 
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and the bowl shape was removed. They had a diffusion area of 0.636 cm2 and a 5 mL 
(approx.) receptor compartment. The receiver volume of each cell was individually calibrated. 
The receiver medium, constituted of pH 7.4 phosphate buffer saline solution, was 
continuously stirred with a small magnetic bar and thermostated at 37±1 °C, so that the skin 
surface temperature was 32±1 °C. At predetermined times, 0.2 mL samples were withdrawn 
from the receiver compartment and replaced with fresh receiver medium. Sink conditions 
were maintained throughout the experiments. Samples were analyzed by HPLC according to 
the method described in the Section 2.8. 
 
2.7.1 Data analysis 
The cumulative amount permeated through the skin per unit area was calculated from the 
concentration of each substance in the receiving medium and plotted as a function of time. 
The steady flux (Jmax) was determined as the slope of the linear portion of the plot. The 
permeability coefficient was calculated according to Fick’s first law of diffusion (equation 1): 
S
J
K P
max=  (1) 
where Kp (cm/h) is the permeability coefficient, Jmax (µg/cm2 per h) is the flux obtained with 
the saturated solution and S is the drug donor concentration (µg/cm3), corresponding to the 
drug solubility in the vehicle at 32 °C. 
 
2.8 Drug assay 
The concentration of S-IB in the medium was determined by HPLC assay (HP 1100, 
Chemstations, Agilent Technologies, USA). A 20 µL sample was injected at 25 ºC on a C18 
reverse-phase column (C18 Nova-Pak, 4.6 x 150 mm - Waters-USA). The wavelength was set 
at 225 nm. The composition of the eluent was acetonitrile:acidified water by phosphoric acid 
at pH 2.6 (60:40 %, v:v) and the flow rate was 1.5 mL/min. A standard calibration curve (1-50 
µg/mL) was used. The limit of quantification was 0.2 µg/mL. Resolution from the 
background noise was adequate at this level. 
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2.9 Monitoring crystal formation 
Appearance of drug crystals was monitored visually and microscopically (Axioscope, Zeiss, 
G) throughout an area of 10 cm2. The monitoring time intervals were daily in the first 2 weeks 
and then bi-weekly over a six-month period. 
 
2.10 Adhesion properties evaluation 
2.10.1 Peel adhesion 180° test 
Two weeks after preparation, a sample of the testing formulation was cut into strips 2.5 cm 
wide, applied to an adherent plate, smoothed three times with a 4.5 Kg roller, maintained for 
10 min at 25 °C and pulled from the plate at 180° angle and at the speed rate of 300 mm/min. 
The 300 mm/min rate and the use of a stainless steel plate were selected as recommended by 
the standard method PSTC101 [7]. The test was performed with a tensile testing machine 
Acquati mod. AG/MC 1 (Acquati, I). The force was expressed in cN/cm width of the plaster 
under test. Peel adhesion values were obtained as average of three replicates. 
 
2.10.2 Creep resistance test 
Two weeks after preparation, the adhesive plasters were cut into strips 2.5 cm wide and 6.0 
cm long. Exactly 2.5 cm of the specimen was applied at the tab end of an adherent panel made 
of stainless steel according to the standard method PSTC107 [8]. The specimen was laid with 
no pressure exactly parallel to the length of the test surface and smoothed 3 times with a 4.5 
Kg roller. The prepared sample was placed in the shear adhesion rack to hold panels 2° 
inclined from vertical so that the back of each panel formed an angle of 178° with the 
extended piece of sample. A weight of 500 g was secured to the free end of the plaster. The 
shear adhesion value is the time taken for the sample to separate from the panel. The test was 
performed with a 8 Bank Oven Shear HT8 instrument (ChemInstrument, USA). Each value is 
the mean of three replicas. 
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3. Results 
 
The stereoisomer exhibited a lower melting point (S-IB Tm=326.9±0.1 K; H=28.32±0.59 
kJ/mol) than the corresponding racemate (RS-IB Tm=350.4±0.0 K; H=39.45±1.81 kJ/mol) 
and, therefore, an higher solubility (S-IB = 127±1 µg/mL; RS-IB = 81±1 µg/mL). 
 
3. 1 Medicated plaster technological characterization 
The data concerning the technological characterization of the plasters are summarized in 
Table 1. In the plaster containing the lowest amount of S-IB, namely 3% w/w in Form no. 1, 
drug crystals grew within a 4-week period as well as in the case of the same formulation 
prepared using RS-IB, where the active ingredient crystallized within 25 days [6]. The 
induction times of the drug crystallization were also comparable in the case of PG (RS-IB 
crystallization time: 50 days; S-IB crystallization time: 60 days) confirming that this excipient 
acted in the matrix mainly as crystallization inhibitor rather than a solubilizing agent [6]. As 
already verified in the case of the racemate, the addition of both 4% PG and 3% EuRL in 
Form. no. 4 inhibited the drug nucleation in plaster containing 3% w/w S-IB for more than 
180 days. The inhibition of drug crystallization in the plasters containing the highest 
percentages of S-IB, namely 4.5% w/w and 6% w/w, resulted possible only in presence of 
PG, keeping constant the S-IB/EuRL ratio at 1/1 (Table 1). 
As far as the adhesive properties is concerned, all the tested plasters stripped cleanly without 
leaving any noticeable residue on the plate during the peel adhesion test and the intra-assay 
standard deviation was always lower than 10%. These features indicated the matrices had 
good cohesive properties. The addition of EuRL significantly reduced the peel values (Form. 
nos 3, 6 and 8 vs Form. no 1, p<0.049) and a good linear correlation between peel adhesion 
values and copolymer concentrations was found (R2= 0.997). Furthermore, adding PG to 
formulation containing EuRL (Form. nos 4, 7 and 10), the peel adhesion values were 
significantly demoted (p<0.05, Table 1). The shear adhesion test confirmed the very low 
creep compliance of the medicated plasters (Table 1). This feature is of particular interest in 
the case of medicated plaster containing an anti-inflammatory drug, such as S-IB, that can be 
applied onto junctures. Indeed, in case of matrices characterized by high creep compliance, a 
plaster applied onto a junctures could partially detach altering the drug permeation through 
the skin. Moreover, the plaster can ooze leaving adhesive residues on its outside edges after 
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the application to the skin. Beside of being unesthetical, adhesive residues can also collect dirt 
and sometime stick to clothing or to other parts of the body. 
As far as the release profiles is concerned, the following remarks can be withdrawn: the 
amounts released from the plasters was dependent on the drug (Form. no. 4 vs 10; Form. no 
11 vs 12, Figure 1), but resulted independent on the use of S-IB and RS-IB (Form. no. 4 vs 
11; Form. no. 10 vs 12, Figure 1). Even if the amount of drug released from the plaster 
increased according to the drug content, the release rate constants calculated according to the 
Higuchi’s equation ranged from 0.793±0.032 h-1 to 0.825±0.017 h-1 and resulted not 
statistically different independently on the drug content or the type of the active ingredient 
used (one way ANOVA, p=0.781). 
 
Table 1 - Composition of the matrices (% m/m), technological characterization and skin 
permeability data of plasters 
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Figure 1 - In vitro release profile of S-IB from Form. nos 4 (▲), 10 ( ), 11 (■) and 12 (□) 
(mean ± st dev, n=3). 
 
3.2 Determination of S-IB and RS-IB skin permeation profiles from solutions and 
plasters 
The amount permeated after 24h (PA24) through the epidermis of the three different donors 
and the Jmax of S-IB or RS-IB from the saturated solutions are summarized in Table 2. 
The permeation data of S-IB obtained by each donor resulted statistically higher than those of 
the racemate, either considering all sets of experiments or evaluating the data by the single 
donor (p<0.002). The same epidermis donors employed for the saturated solutions were used 
to determine the skin permeation using Form. nos 4 and 11 containing 3% w/w S-IB and RS-
IB, respectively. The skin permeability data, reported in Table 3, revealed that no differences 
were noticeable between the enantiomer and the racemate. Indeed, both the fluxes and the 
amounts permeated after 24 h of SIB (Form. no 4) resulted not statistically different with 
respect to those determined using Form. no 11 either considering all sets of experiments or 
evaluating the data by the single donor (p>0.17). 
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Considering that the final goal of this study was also the evaluation of the skin permeation of 
the two selected compounds, the impact of the formulative variables, namely drug 
concentration and drug/crystallization inhibitor ratios, was directly evaluated by in vitro skin 
permeation test using epidermis samples from another single donor. The skin permeation 
profiles of the medicated plasters containing S-IB are summarized in Table 1 and the S-IB 
permeation profiles from Form. nos 1-4 are shown in Figure 2 as an example. In the case of 
the plaster prepared without any crystallization inhibitor (Form. no 1), the permeation profile 
resulted not linear. Such lack of linearity was attributed to a progressive nucleation process 
and crystal growth during the experiment and, therefore, to a decrease of the drug activity in 
the matrix. In fact, at the end of the experiment, drug crystals were clearly evident in the 
adhesive matrix by visual inspection. The S-IB skin permeation profiles, determined using the 
plasters prepared by adding EuRL, PG or a mixture thereof to the matrix containing 3% w/w 
S-IB (Form. nos 2-4), resulted superimposable (p >0.05). Increasing the drug and EuRL 
contents (Form. nos 3, 6 and 8), an increase of the flux through the human epidermis was 
found (Table 1). Nevertheless, this trend did not result statistically significant. The presence 
of PG in Form. nos 4, 7 and 10 did not further modify the drug permeation profiles (Table 1). 
The data evidenced that the considered formulative variables and the strong increase of the 
drug content did not improve skin permeation of S-IB. 
 
Table 2 - Permeated amounts after 24 h (PA24) and fluxes (Jmax) of RS-IB or S-IB vehicled in 
aqueous solutions (mean ± .st dev., n=3). 
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Table 3 - Permeated amounts after 24 h (PA24) and fluxes (Jmax) of RS-IB or S-IB vehicled 
in plasters (mean ± st. dev., n=3). 
 
 
 
Figure 2 - S-IB ex vivo skin permeation profile from formulations nos 1-4 (mean ± st. dev., 
n=3). 
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4. Discussion 
 
As far as the in vitro human skin permeation studies are concerned, the data obtained from 
saturated solutions were in agreement with the physico-chemical characteristics of the two 
compounds. As a matter of fact, it has been reported that enantiomers of chiral compounds 
with a lower melting point than their racemates, as in the case of S-IB and RS-IB, have 
usually higher solubility and, consequently, greater flux through the skin than those of the 
racemates [9 ]. The experimental permeation data fit also with the mathematical model, the 
melting temperature-membrane transport (MTMT) concept, based on the interdependence of 
the physicochemical characteristics, namely melting temperature, and the membrane transport 
behaviour of a chiral penetrant, which was used to predict the permeability ratio of 
enantiomers and racemates of chiral molecules [4, 10]. According to this model, the ratio of 
the fluxes of a chiral compound and the corresponding racemate through the skin are mainly 
dependent upon their solubility and, consequently, a strict relationship between thermal 
features and skin permeability exists. Such relationship is expressed by the following 
equation: 
 ( ) ( )
TTmR
TTmH
TTmR
TTmH
S
S
J
J
S
SS
RS
RSRS
RS
S
RS
S
⋅⋅
−⋅∆−⋅⋅
−⋅∆== lnln  (2) 
 
where T is temperature at which the experiment is carried out (305 K), R is the universal gas 
constant and other terms can be interpreted as described in earlier sections. In our case, the 
theoretical Js/Jrs value, calculated according to the equation reported above, was 3.55 which 
resulted very close to the experimental value (Jmax,s / Jmax,rs = 3.00±0.59). If the permeation 
data obtained by saturated solutions were in agreement with the theory, e.g. the most soluble 
compound allows to obtain a higher flux, the results obtained by using the plasters were 
unexpected. Indeed, neither the chirality of ibuprofen nor its concentration in the plaster 
influenced the permeation process of the drug. Considering that both RS-IB and S-IB rapidly 
crystallized in the dry matrix (Table 1), it is reasonable to assume that both the active 
ingredients were in supersaturated conditions in the plasters [6]. Even if it was not possible to 
determine experimentally the solubility of RS-IB and S-IB in the plaster matrix, on the bases 
of their thermal data, the solubility of RS-IB would be lower with respect to that of S-IB. As a 
consequence, considering that the concentrations of the pure enantiomer and racemate are 
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identical in Form. nos. 4 and 11 (Table 1), the supersaturation degree of S-IB should be lower 
than that of RS-IB and, therefore, the S-IB flux should result lower than that measured for 
RS-IB. The lack of differences in the Jmax,s and Jmax,rs could be justified supposing that the drug 
thermodynamic activity in the adhesive matrix was not the main limiting step in the 
permeation process, but other factors could deeply influence the drug release from the 
plasters. The lack of differences in the in vitro release rate constants verified by the 
dissolution test indicated also that the skin absorption of the ibuprofen vehicled in the plasters 
was probably limited by its diffusivity in the adhesive matrix rather than its diffusion through 
the human epidermis. 
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4. Conclusion 
 
The statistical analyses revealed that the Jmax of S-IB vehicled in saturated solution resulted 
higher than that of RS-IB according to the theory. When supersaturated silicon plasters were 
used, the flux through the skin resulted independent of the drug loading and chirality. The 
comparison of all set of permeation data evidenced that depending on the vehicle and the use 
of racemate or enantiomer, the ibuprofen fluxes followed the rank order S-IB vehicled in 
saturated solution > SIB vehicled in plaster ≈ RS-IB vehicled in plaster > RS-IB vehicled in 
saturated solution. In conclusion, the proposed plasters containing RS-IB determine a 
significant increase of the flux with respect to the corresponding saturated solution; when S-
IB was used, the enhancement effect of the supersaturation was limited by the diffusivity of 
the active ingredient in the silicon matrix. 
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This work demonstrated the feasibility to administrate propranolol and ibuprofen by 
transdermal patches. 
As far as the in vitro human skin permeation studies are concerned, the data obtained from 
saturated solutions were generally in agreement with the physico-chemical characteristics of 
the chiral permeant: the most soluble compound allows to obtain a higher flux. However, the 
MTMT concept appears a too simple approach for estimating differences between the 
racemate and the enantiomers if the solvent has an unexpected role in influencing the 
association and/or the aggregation of the solutes, or if the drug is loaded in a complex matrix.  
The results obtained by using the patches did not evidence a different permeation flux for the 
(S)-enantiomer and the racemate when ibuprofen or propranolol were used. This lack of 
differences in the Jmax,s and Jmax,rs could be justified supposing that the drug thermodynamic 
activity in the adhesive matrix was not the main limiting step in the permeation process, but 
other factors could deeply influence the drug skin permeation as the drug release from the 
patches, probably limited by its diffusivity in the adhesive matrix. 
